# Joachim Rothe

> Joachim Rothe is a Series B investor at EQT Life Sciences backing Biotechnology and Health Care. See 14 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [EQT Life Sciences](https://shizune.co/investors/profile/life-sciences-partners)
- Location: Munich, Germany
- Total investments: 14
- Last investment: Apr 2024
- Lead investor: 29%
- Last updated: Aug 2026
- LinkedIn: http://de.linkedin.com/pub/joachim-rothe/93/693/927

Joachim Rothe is a Series B investor at EQT Life Sciences in Munich focused on Biotechnology and Health Care. Joachim (JR) Rothe, PhD, joined LSP in 2002. He became a Partner and co-owner of the firm in that same year. His prime focus and responsibility within LSP is to invest in unlisted securities and the general management of the firm. Prior to joining LSP, Joachim was the Managing Director of MPM Capital Germany, a US healthcare investment firm,where he rose to head up their European investment franchise. Previously, he worked at McKinsey & Company in Germany and at Hoffmann-La Roche in Switzerland. Joachim brings a strong scientific background and in-depth knowledge of the pharmaceutical and biotechnology industries to the LSP team. He has been appointed a Director of a large number of companies, all of which he has helped to grow by leveraging his scientific expertise, pharmaceutical experience and global networks. Among others, Joachim is currently a Director at Atlas Genetics, a UK diagnostic company developing ultra-rapid point-of-care tests for a range of infectious diseases. Joachim obtained a Master’s degree in Biochemistry from the Free University in Berlin and a PhD in Molecular Immunology from Freiburg University. His thesis was supervised by Georges Köhler, a Nobel laureate in Medicine. Joachim has authored numerous articles in leading scientific publications, including Nature. Joachim lives in Munich with his wife and two children.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 43% |
| Health Care | 4 | 29% |
| Medical | 3 | 21% |
| Mobile | 1 | 7% |
| Genetics | 1 | 7% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 4 | 29% |
| Series A | 2 | 14% |
| Series C | 2 | 14% |
| Series D | 1 | 7% |
| Series E | 1 | 7% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Germany | 2 | 14% |
| Spain | 1 | 7% |
| France | 1 | 7% |
| Switzerland | 1 | 7% |
| United States | 1 | 7% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Binx Health | Binx Health is creating new categories of healthcare solutions that deliver on-demand testing to people where they need it most. With its proprietary, desktop, PCR-based point-of-care testing platforms and consumer mobile offerings, the company is redefining “convenient care” for the modern consumer | $65M | Series F | Apr 02, 2024 |  |
| DNA Script | DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Their revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results. | $165M | Series C | Oct 26, 2021 |  |
| Innovative Molecules | Innovative Molecules develops drugs designed to treat Herpes simplex-induced diseases. | $24.4M | Series A | Jun 09, 2021 |  |
| Binx Health | Binx Health is creating new categories of healthcare solutions that deliver on-demand testing to people where they need it most. With its proprietary, desktop, PCR-based point-of-care testing platforms and consumer mobile offerings, the company is redefining “convenient care” for the modern consumer | $104M | Series E | May 27, 2021 |  |
| DNA Script | DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Their revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results. | $50M | Series B | Jul 29, 2020 |  |
| DNA Script | DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Their revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results. | $38.5M | Series B | May 16, 2019 |  |
| Nouscom | Nouscom are a well established team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos, and are veterans in the field of oncolytic and genetic vaccines. The company is headquartered in Basel, Switzerland and has operations in Rome, Italy.The NousCom team is lead by experiencedenterpreneurs that worked together for many years in previous successful enterprises, such as Okairos, under the leadership of Prof. Riccardo Cortese, who conceived the ideas behind those companies. | $44.6M | Series B | Nov 06, 2017 |  |
| Binx Health | Binx Health is creating new categories of healthcare solutions that deliver on-demand testing to people where they need it most. With its proprietary, desktop, PCR-based point-of-care testing platforms and consumer mobile offerings, the company is redefining “convenient care” for the modern consumer | $35M | Series D | Jan 23, 2017 |  |
| Luxendo | Luxendo will manufacture and sell advanced Single Plane Illumination Microscopes (SPIM) originally developed at EMBL by Lars Hufnagel and his team. SPIM is a rapidly emerging technology that combines optical sectioning with multiple-view imaging to observe tissues and living organisms with impressive resolution. Unlike the conventional techniquesof widefield and confocal fluorescence microscopy, the light sheet technique illuminates on the region surrounding the focal plane of the detection objective in a twin objective configuration. | $8.8M | Series A | Jan 12, 2017 |  |
| Luxendo | Luxendo will manufacture and sell advanced Single Plane Illumination Microscopes (SPIM) originally developed at EMBL by Lars Hufnagel and his team. SPIM is a rapidly emerging technology that combines optical sectioning with multiple-view imaging to observe tissues and living organisms with impressive resolution. Unlike the conventional techniquesof widefield and confocal fluorescence microscopy, the light sheet technique illuminates on the region surrounding the focal plane of the detection objective in a twin objective configuration. | $6.6M | Series A | Oct 14, 2015 |  |

10 of 14 investments shown.

## Co-investors
- [Illumina Ventures](https://shizune.co/investors/profile/illumina-ventures) — VC Fund, 3 deals together
- [Johnson & Johnson Development Corporation](https://shizune.co/investors/profile/johnson-johnson-development-corporation) — VC Fund, 3 deals together
- [Agilent Technologies](https://shizune.co/investors/profile/agilent) — VC Fund, 2 deals together
- [ArrowMark Partners](https://shizune.co/investors/profile/arrowpoint-partners) — VC Fund, 2 deals together
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 2 deals together
- [Casdin Capital](https://shizune.co/investors/profile/casdin-capital) — VC Fund, 2 deals together

## About EQT Life Sciences

VC Fund · Amsterdam, The Netherlands

EQT life science develops innovative medicines, devices, and tools to address the single important thing that matters to the preservation of health. The organization believes that such opportunities add value to all stakeholders.

5 contacts available at EQT Life Sciences.

| Name | Title | Profile |
| --- | --- | --- |
| Christoph Broja | Partner | https://shizune.co/investors/profile/christoph-broja-c9a3 |
| Fouad Azzam | General Partner | https://shizune.co/investors/profile/fouad-azzam |
| Joachim Rothe | General Partner | https://shizune.co/investors/profile/joachim-rothe |
| Daniela Begolo | Managing Director | https://shizune.co/investors/profile/daniela-begolo |
| Ellen Cordo | Chief Finance | https://shizune.co/investors/profile/ellen-cordo |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Joachim Rothe invest in?

Joachim Rothe invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 14 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Joachim Rothe last invest?

The most recent investment recorded for Joachim Rothe closed in Apr 2024. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co